April 24, 2015
Strategia Therapeutics Inc., formerly Boston Strategics Corporation, has said that it has started a PI/IIa clinical study of the cancer agent E6201 in the US. The study enrolls patients with advanced hematologic malignancies, including relapsed or refractory acute myeloid leukemia,...read more